Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Soto, A. Martin, P. de Lucas, J. M. Rodriguez Gonzalez-Moro (Madrid, Spain). Economic evaluation of beclomethasone/formoterol versus budesonide/formoterol in the treatment of patient with moderate-severe asthma in Spain. Eur Respir J 2008; 32: Suppl. 52, 2665

Member's Comments

No comment yet.

Related content which might interest you: Pharmacoeconomic analysis of beclomethasone/formoterol versus fluticasone/salmeterol in the treatment of moderate-severe asthma in Spain Source: Annual Congress 2008 - Impact of patient education on cost-effectiveness of treatment Year: 2008 Economic evaluation of salmeterol/fluticasone propionate combination vs budesonide/formoterol in Spain Source: Annual Congress 2003 - Management of asthma in primary care Year: 2003 Benefit of budesonide/formoterol compared with salmeterol/fluticasone in COPD patients in the morning Source: Annual Congress 2009 - Healthcare and treatment of COPD Year: 2009 Real-life evaluation of budesonide/formoterol (DuoResp Spiromax) for the management of asthma and COPD in the UK Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017 A new budesonide/formoterol inhalation therapy in patients with asthma, COPD and ACOS Source: International Congress 2017 – Bronchial asthma management Year: 2017 Cost-effectiveness of adding budesonide/formoterol to tiotropium in severe COPD patients in four Nordic countries Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012 Mite-induced asthma treatment: Budesonide/formoterol vs. fluticasone/salmeterol Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010 Efficacy and safety of fluticasone/formoterol compared to fluticasone alone in patients with asthma Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012 Efficacy of salmeterol/fluticasone pMDI versus DPI in patients with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 499s Year: 2006 Cost effectiveness of budesonide/formoterol vs fluticasone/salmeterol: Real-world effectiveness and safety in COPD Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 Improvement in health status in patients with moderate to severe COPD after treatment with budesonide/formoterol in a single inhaler Source: Eur Respir J 2002; 20: Suppl. 38, 250s Year: 2002 Economic evaluation of salmeterol/fluticasone combination versus budesonide plus formoterol in Spain Source: Eur Respir J 2001; 18: Suppl. 33, 49s Year: 2001 Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Source: Eur Respir J 2005; 26: 819-828 Year: 2005 Impact of adherence to treatment with tiotropium co-administered with fluticasone propionate/salmeterol combination in COPD patients Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006 Efficacy of aclidinium/formoterol fixed-dose combination versus salmeterol/fluticasone in COPD Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 QVA149 is more efficacious than tiotropium and salmeterol/fluticasone combination (SFC) in improving patient-reported outcomes and lung function in COPD patients with moderate-to-severe baseline dyspnoea: The IGNITE trials Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015 Budesonide/formoterol single inhaler therapy (SiT) provides superior asthma control compared with fixed dose (FD) budesonide or budesonide/formoterol in patients with severe persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 509s Year: 2004